JACoW is a publisher in Geneva, Switzerland that publishes the proceedings of accelerator conferences held around the world by an international collaboration of editors.
@unpublished{tadokoro:linac2022-we2aa03,
author = {T. Tadokoro},
title = {{Medical Radioisotopes Production Focusing on Ra-225/Ac-225, Cu-67 and Mo-99/Tc-99m Using an Electron Linear Accelerator}},
booktitle = {Proc. LINAC'22},
language = {english},
intype = {presented at the},
series = {International Linear Accelerator Conference},
number = {31},
venue = {Liverpool, UK},
publisher = {JACoW Publishing, Geneva, Switzerland},
month = {09},
year = {2022},
note = {presented at LINAC'22 in Liverpool, UK, unpublished},
abstract = {{Ac-225 is a descendant nuclide of Ra-225 and has nuclear properties that make it well suited for use in targeted alpha therapy. However, Ac-225-radiopharmaceutical development has been prevented by insufficient supplies of Ac-225. An electron linac based Ra-225/Ac-225 production system has many advantages: the size of the system is relatively small, a high beam current is easily achieved and the cross section of the Ra-225 production reaction, Ra-225(gamma, n)Ra-225, is relatively high. Moreover, the production amounts of impurity nuclides are very small. These advantages can lead to a cost-effective system. With the final goal of implementing such a system, we have been evaluating the Ra-225/Ac-225 production amount in a real-scale system. To provide more cost-effectiveness, we have been considering production of other medical nuclides using the same system. Cu-67 is recently being studied as nuclides for treatment agents. Mo-99 is a parent nuclide of Tc-99m and commonly used in nuclear medicine. We also have carried out the evaluation of Cu-67 and Mo-99/Tc-99m production amounts. The R&D project of radioisotope production using electron linac will be presented in this conference.}},
}